Restricting Fluids Post Abdominal Surgery Doesn't Up Survival

Share this content:
Restricting Fluids Post Abdominal Surgery Doesn't Up Survival
Restricting Fluids Post Abdominal Surgery Doesn't Up Survival

THURSDAY, May 10, 2018 (HealthDay News) -- A restrictive fluid regimen is not associated with increased disability-free survival for patients at increased risk of complications during major abdominal surgery, but is associated with increased acute kidney injury, according to a study published online May 10 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the Australian and New Zealand College of Anaesthetists, held from May 7 to 11 in Sydney.

Paul S. Myles, M.P.H., D.Sc., from Monash University in Melbourne, Australia, and colleagues randomized 3,000 patients who had an increased risk of complications while undergoing major abdominal surgery to receive a restrictive or liberal intravenous-fluid regimen during and up to 24 hours after surgery (1,490 and 1,493 patients, respectively).

The researchers found that at one-year, the rate of disability-free survival was 81.9 and 82.3 percent in the restrictive and liberal fluid groups, respectively (hazard ratio for death or disability, 1.05; 95 percent confidence interval, 0.88 to 1.24; P = 0.61). The rate of acute kidney injury was 8.6 and 5.0 percent in the restrictive and liberal fluid groups, respectively (P < 0.001).

"Among patients at increased risk for complications during major abdominal surgery, a restrictive fluid regimen was not associated with a higher rate of disability-free survival than a liberal fluid regimen and was associated with a higher rate of acute kidney injury," the authors write.

Abstract/Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »